Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. J of Skin 2025, 9 (6), s616. https://doi.org/10.25251/n1p8w126.